J. G. Posada

Diaziquone (AZQ)

J. Bender, A. Grillo-López, J. G. Posada, 2004, Investigational New Drugs.

Chapter 55 – Monoclonal Antibody Therapy of Cancer

A. Frankel, J. G. Posada, 2008 .

Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group.

M. Buyse, C. Geyer, N. Wolmark, 2011, Clinical breast cancer.

Amsacrine-associated cardiotoxicity: an analysis of 82 cases.

S. Marsoni, R. Weiss, J. G. Posada, 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Anaphylactic reactions to diaziquone.

P. O'dwyer, D. Hoth, J. G. Posada, 1984, Cancer treatment reports.

Images in clinical medicine. Von Recklinghausen's disease and breast cancer.

C. Chakmakjian, J. G. Posada, 2005, New England Journal of Medicine.

Nephrotoxicity of semustine.

M. Boyd, R. Weiss, R. Kramer, 1983, Cancer treatment reports.

The cyclophosphamide, hexamethylmelamine, 5 fluorouracil (CHF) regimen in the treatment of advanced and recurrent ovarian cancer.

B. Edwards, P. Schein, F. Smith, 1985, Gynecologic oncology.